Published in Exp Hematol on February 01, 1998
Possible prognostic and therapeutic significance of c-Kit expression, mast cell count and microvessel density in renal cell carcinoma. Int J Mol Sci (2014) 0.88
Tetraspanins in mast cells. Front Immunol (2012) 0.84
Mast cell activation is characterized by upregulation of a functional anaphylatoxin C5a receptor. BMC Immunol (2008) 0.82
Interleukin-3 does not affect the differentiation of mast cells derived from human bone marrow progenitors. Immunol Invest (2008) 0.80
Immunosurveillance function of human mast cell? World J Gastroenterol (2005) 0.79
A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost (1981) 4.39
Gene organization and structure of two transcriptional units from Methanococcus coding for ribosomal proteins and elongation factors. Can J Microbiol (1989) 3.38
Survey of medical training in cytopathology carried out by the journal Cytopathology. Cytopathology (2010) 3.32
A view of Neandertal genetic diversity. Nat Genet (2000) 3.31
Transcription of mouse rDNA terminates downstream of the 3' end of 28S RNA and involves interaction of factors with repeated sequences in the 3' spacer. Cell (1985) 3.03
Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med (2000) 2.96
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med (2000) 2.86
MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst (1991) 2.50
A repeated 18 bp sequence motif in the mouse rDNA spacer mediates binding of a nuclear factor and transcription termination. Cell (1986) 2.46
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia (2008) 2.44
Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc (2008) 2.29
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy (2003) 2.08
Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 2.07
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Ann Oncol (2010) 1.86
Antithrombin III deficiency and thromboembolism. Clin Haematol (1981) 1.76
Evidence of HLA-DR antigen biosynthesis by human keratinocytes in disease. J Exp Med (1984) 1.75
The role of breast FNAC in diagnosis and clinical management: a survey of current practice. Cytopathology (2008) 1.75
Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem (1998) 1.74
Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science (1991) 1.62
Basophils are not the key antigen-presenting cells in allergic patients. Allergy (2012) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Prevention of latex allergy by selection of low-allergen gloves. Clin Exp Allergy (2000) 1.55
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res (2001) 1.48
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
Solid tumors and factor VIII antibodies. Thromb Haemost (1999) 1.48
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med (1997) 1.44
What have mast cells to do with edema formation, the consecutive repair and fibrinolysis? Int Arch Allergy Immunol (1998) 1.44
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol (2002) 1.44
Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group. Ann Intern Med (1990) 1.44
Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol (2004) 1.43
The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging (2001) 1.43
Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med (2001) 1.43
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol (2009) 1.43
Longevity of direct resin composite restorations in posterior teeth. Clin Oral Investig (2003) 1.42
Major bleeding complications after cardiopulmonary resuscitation: impact of thrombolytic treatment. J Intern Med (2003) 1.42
Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells. Wien Klin Wochenschr (1998) 1.39
Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features. Thromb Haemost (2000) 1.39
A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost (1982) 1.39
Thrombocytopenia associated with low-molecular-weight heparin. Lancet (1991) 1.39
Novel CBF beta-MYH11 fusion transcripts and alternative splicing in acute myeloid leukemia with inversion of chromosome 16. Blood (1995) 1.38
Profilins constitute a novel family of functional plant pan-allergens. J Exp Med (1992) 1.35
Report of the Working Party on Acquired Inhibitors of Coagulation: studies of the "lupus" anticoagulant. Thromb Haemost (1983) 1.34
Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis (1985) 1.34
Interleukin-3 is a differentiation factor for human basophils. Blood (1989) 1.34
Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood (1989) 1.33
Glycosylated hemoglobins (GHb): an index of red cell survival. Blood (1982) 1.32
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest (2009) 1.32
Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol (1998) 1.28
Impact of HLA class I high-resolution mismatches on chronic graft-versus-host disease and survival of patients given hematopoietic stem cell grafts from unrelated donors. Bone Marrow Transplant (2005) 1.28
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Acquired inhibitors in nonhemophilic patients. Haemostasis (1974) 1.26
Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci U S A (1989) 1.26
Power consumption in shaking flasks on rotary shaking machines: II. Nondimensional description of specific power consumption and flow regimes in unbaffled flasks at elevated liquid viscosity. Biotechnol Bioeng (2000) 1.25
Peripheral nerve lesions in haemophilia. J Neurol (1981) 1.25
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis (1980) 1.22
Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest (1997) 1.22
Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J (2001) 1.21
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res (2001) 1.17
Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J (1999) 1.17
Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol (1999) 1.17
Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma (2000) 1.16
Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol (2006) 1.16
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med (1994) 1.15
Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation. Bone Marrow Transplant (2002) 1.14
Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies. Allergy (2006) 1.14
Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc Natl Acad Sci U S A (1991) 1.13
Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol (2001) 1.13
Protein C deficiency in two Austrian families. Thromb Haemost (1983) 1.12
Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol (1994) 1.12
The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood (1994) 1.12
Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol (2001) 1.11
Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. Lab Invest (1996) 1.11
Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest (2007) 1.11
1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol (2000) 1.10
Failure to detect IL-3-binding sites on human mast cells. J Immunol (1990) 1.10
European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology (2007) 1.10
Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes. Immunology (1996) 1.09
Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest (2008) 1.08
The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood (1999) 1.08
Hemophilia and thrombocytopenia in a patient with impaired cellular immunity. A case report. Blut (1984) 1.08
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Thromb Haemost (1979) 1.08
Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J (2001) 1.08
[Gangrene following erroneous intra-arterial injection of dicloxacillin]. Dtsch Med Wochenschr (1971) 1.08
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood (1995) 1.07